| Objective:To observe the clinical efficacy and safety of Huaganxian Decoction in the treatment of chronic hepatitis B liver fibrosis,and to provide scientific basis for the further clinical promotion and application of Huaganxian Decoction.Methods:A total of 60 patients who met the inclusion criteria were collected and divided into a control group and an observation group according to the random number table,with 30 cases in each group.The control group was treated with Compound Biejia Ruangan tablets combined with entecavir capsules,and the observation group was treated with Huaganxian decoction combined with entecavir capsules.The treatment course of the two groups was 12 weeks.The differences in liver function(ALT,AST),HBV-DNA negative conversion rate,serum liver fibrosis four items(HA,LN,PCⅢ,CIV),liver stiffness measurement(LSM),TCM clinical symptom score and curative effect were compared between the two groups before and after treatment.Results:1)Liver function:after treatment,AST and ALT were decreased as compared with those before treatment in the two groups(P<0.05),and the decreases of AST and ALT in the observation group were more significant than those in the control group(P<0.05).2)HBV-DNA negative conversion rate:after treatment,the number of HBV-DNA positive patients in the two groups was significantly lower than that before treatment,and the number of HBV-DNA negative patients was significantly higher than that before treatment(P<0.05),but there was no significant difference in the negative conversion rate between the two groups(P>0.05).3)Liver fibrosis indicators:after treatment,the serum HA,LN,PCⅢ and CIV levels in the two groups were lower than those before treatment(P<0.05),but the serum HA,LN,PCⅢ and CIV levels in the observation group were lower than those in the control group(P<0.05).Comparison of LSM:after treatment,LSM in the two groups decreased(P<0.05),but the LSM value in the observation group was lower than that in the control group(P<0.05).4)TCM syndrome scores:after treatment,the TCM syndrome scores of the two groups were lower than those before treatment(P<0.05),but the TCM syndrome score of the observation group was lower than that of the control group(P<0.05).The total effective rate of the observation group was 93.33%,which was higher than 86.67%of the control group(P<0.05).Conclusion:1)Huaganxian decoction is superior to Fuzheng Huayu capsule in improving liver function indexes,reducing liver fibrosis four items and LSM levels,and increasing HBV-DNA negative conversion rate in patients with chronic hepatitis B liver fibrosis.2)Huaganxian decoction is superior to Fuzheng Huayu capsule in reducing TCM syndrome score and improving clinical symptoms.3)Huaganxian decoction has high safety in clinical application. |